Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Akari Therapeutics PLC AKTX

Healthcare Biotechnology
Akari Therapeutics, Plc is a late-stage biotechnology company. The Company is developing advanced therapies for autoimmune and inflammatory diseases. Its lead asset, investigational nomacopan, is a bispecific recombinant inhibitor of complement C5 activation and leukotriene B4 (LTB4) activity. Its pipeline includes a Phase 3 clinical trial program investigating nomacopan for pediatric... see more

Recent & Breaking News (NDAQ:AKTX)

Akari Therapeutics Announces New Data with Nomacopan from its Surface of the Eye Program

GlobeNewswire October 25, 2021

Akari Therapeutics to Present at the Cantor Virtual Global Healthcare Conference

GlobeNewswire September 22, 2021

Akari Therapeutics Reports Second Quarter 2021 Financial Results and Highlights Recent Clinical Progress

GlobeNewswire September 22, 2021

Akari Therapeutics to Present Its Phase III Plans for Nomacopan in Patients with Bullous Pemphigoid at the 2021 International Pemphigus & Pemphigoid Foundation (IPPF) Scientific Symposium

GlobeNewswire September 10, 2021

Akari Therapeutics to Present at the H.C. Wainwright Global Investment Conference

GlobeNewswire September 7, 2021

Akari Therapeutics Announces Private Placement

GlobeNewswire July 7, 2021

Akari Therapeutics Reports Q1 2021 Financial Results and Highlights Recent Clinical Progress

GlobeNewswire June 29, 2021

Akari Therapeutics Receives FDA Fast Track Designation for Nomacopan for the Treatment of Bullous Pemphigoid

GlobeNewswire April 28, 2021

Akari Therapeutics Announces Poster Presentation of Phase II Bullous Pemphigoid Disease and Phase III Trial Design at American Academy of Dermatology Association Virtual Meeting Experience

GlobeNewswire April 22, 2021

Akari Therapeutics Reports Full Year 2020 Financial Results and Highlights Recent Clinical Progress

GlobeNewswire April 20, 2021

Akari Therapeutics Announces Initiation of Pivotal Phase III Trial of Nomacopan in Bullous Pemphigoid (BP)

GlobeNewswire April 12, 2021

Akari Therapeutics Announces a Cooperative Research and Development Agreement (CRADA) with the U.S. Army Institute of Surgical Research (USAISR) for Nomacopan in Trauma

GlobeNewswire March 4, 2021

Akari Therapeutics Presents New Preclinical Data Highlighting Potential of Long-Acting PASylated Nomacopan to Treat Retinal Diseases, Including Age-Related Macular Degeneration (AMD) and Uveitis

GlobeNewswire February 25, 2021

Akari Therapeutics Adds Histamine Inhibitor Votucalis to Pipeline to treat Neuropathic Pain and Dermatological Disease

GlobeNewswire February 1, 2021

Akari Therapeutics to Participate in Two January Virtual Investor Conferences

GlobeNewswire January 6, 2021

Akari Therapeutics Reports Third Quarter 2020 Financial Results and Highlights Recent Clinical Progress

GlobeNewswire December 11, 2020

Akari Therapeutics Announces New Clinical Data that Show Long-Term Self-Administered Nomacopan is Well-Tolerated and Substantially Reduces Transfusion Dependence in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH)

GlobeNewswire December 11, 2020

Akari Therapeutics Announces Publication in American Journal of Pathology Highlighting Potential of Nomacopan in Treatment of Uveitis and Retinal Disease

GlobeNewswire December 3, 2020

Akari Therapeutics to Present Phase II Data from Bullous Pemphigoid Trial at European Academy of Dermatology and Venereology (EADV) Virtual Congress October 29

GlobeNewswire October 27, 2020

Akari Therapeutics Announces Further Clinical Trial Progress Using Nomacopan to Treat COVID-19 Pneumonia

GlobeNewswire October 6, 2020